SCHEMBL6975583

SCHEMBL6975583

CCC(C)CN1CCC(C(=O)O)CC1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
S1PR5 Q9H228 4/20 0.41
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LTA4H P09960 1/20 0.37
S1PR4 O95977 1/20 0.37
S1PR1 P21453 1/20 0.37
S1PR3 Q99500 1/20 0.37
SLC18A3 Q16572 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22861611 0.84 ALDH1A1 (0.39) SMN1; SMN2S1PR5LMNAMEN1KMT2A
SCHEMBL321619 0.83 PIK3CD (0.50) SMN1; SMN2S1PR5LMNAALDH1A1KDM4E
SCHEMBL28098432 0.81 L3MBTL1 (0.40) SMN1; SMN2S1PR5LMNAALDH1A1KDM4E
SCHEMBL1440004 0.81 SMN1; SMN2 (0.41) SMN1; SMN2S1PR5LMNAALDH1A1L3MBTL1
SCHEMBL1048787 0.81 SMN1; SMN2 (0.44) SMN1; SMN2S1PR5LMNAALDH1A1L3MBTL1
SCHEMBL12465587 0.80 SMN1; SMN2 (0.39) SMN1; SMN2S1PR5LMNAALDH1A1KDM4E
SCHEMBL19622374 0.77 SHBG (0.39) MEN1KMT2AALDH1A1KDM4ESLC18A3
SCHEMBL855052 0.77 SMN1; SMN2 (0.67) SMN1; SMN2S1PR5LMNAALDH1A1KDM4E
SCHEMBL11308867 0.76 SMN1; SMN2 (0.39) SMN1; SMN2S1PR5LMNAALDH1A1KDM4E
SCHEMBL15354735 0.76 HSD11B1 (0.54) SMN1; SMN2LMNAMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303513-A1 N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL] CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES Bristol-Myers Squibb Company (US) 2003-04-23 EP disclosed
EP-1282419-A2 METHODS FOR PREVENTING AND TREATING ALOPECIA INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY BRISTOL-MYERS SQUIBB COMPANY (US) 2003-02-12 EP disclosed
EP-1240166-A1 N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-09-18 EP disclosed
WO-2002010162-A1 N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL] CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-02-07 WO disclosed
WO-2001044242-A9 N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES BRISTOL MYERS SQUIBB CO (US) 2001-11-08 WO disclosed
WO-2001080813-A2 METHODS FOR PREVENTING AND TREATING ALOPECIA INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY BRISTOL-MYERS SQUIBB COMPANY (US) 2001-11-01 WO disclosed
WO-2001044242-A1 N-[5-[[[5-ALKYL-2-OXAZOLYL]METHYL]THIO]-2-THIAZOLYL]CARBOXAMIDE INHIBITORS OF CYCLIN DEPENDENT KINASES BRISTOL-MYERS SQUIBB CO. (US) 2001-06-21 WO disclosed